Company news

Amgen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

FDA approves BLINCYTO® (blinatumomab) in CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase

June 13, 2024

Amgen to present innovative rheumatology research at EULAR 2024

June 11, 2024

Amgen to present at goldman sachs 45th annual global healthcare conference

June 4, 2024

Amgen announces positive results for phase 3 registrational trial evaluating uplizna® (inebilizumab-cdon) for treatment of immunoglobulin G4-related disease (IgG4-RD)

June 4, 2024

Amgen to present innovative research from its robust oncology portfolio at ASCO 2024

May 27, 2024

New data presented at ats 2024 show the potential of TEZSPIRE® to help patients living with COPD

May 18, 2024

FDA approves IMDELLTRA™ (tarlatamab-dlle), the first and only t-cell engager therapy for the treatment of extensive-stage small cell lung cancer

May 15, 2024

Amgen to host conference call following ats 2024

May 14, 2024

Amgen reports first quarter 2024 financial results

May 1, 2024

Amgen highlights new COPD, asthma and vasculitis research at ats 2024

April 30, 2024

Amgen announces webcast of 2024 first quarter financial results

April 28, 2024

Amgen to submit teprotumumab marketing authorization application to the European Medicines Agency

April 25, 2024

Amgen to present TEZSPIRE® Phase 2A COPD data at ats 2024

April 15, 2024

Amgen presents new research on Otezla® (Apremilast) at AAD 2024

March 8, 2024

Amgen announces 2024 second quarter dividend

March 5, 2024

Amgen to present at the 44th annual td cowen health care conference

February 28, 2024

Amgen opens state-of-the-art biomanufacturing site in Central Ohio

February 25, 2024

Amgen to host conference call on rare disease

February 18, 2024

Amgen to present at the 34th annual oppenheimer healthcare life sciences conference

February 8, 2024

Amgen reports fourth quarter and full year 2023 financial results

February 5, 2024

Amgen announces webcast of 2023 fourth quarter and full year financial results

January 31, 2024

deCODE genetics: A sequence variant that increases risk of pregnancy loss

January 28, 2024

Amgen to present at the 42nd annual j.p. morgan healthcare conference

January 2, 2024

Amgen provides regulatory update on status of LUMAKRAS® (sotorasib)

December 25, 2023

Amgen to sponsor the Irish Open

December 13, 2023

Amgen announces executive appointments to accelerate innovation

December 13, 2023

FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer

December 12, 2023

Amgen announces 2024 first quarter dividend increase to $2.25 per share

December 11, 2023

Amgen highlights hematology portfolio at ASH 2023

December 7, 2023

Amgen to present at the evercore isi healthconx conference

November 21, 2023

Amgen presents new cardiovascular research at AHA 2023

November 9, 2023

Amgen presents new research in early psoriatic arthritis at ACR 2023

November 6, 2023

Amgen presents new data from Phase 2 trial of dazodalibep in Sjögren's syndrome at ACR 2023

November 6, 2023

Amgen presents new data that show blood pressure decreases for adults treated with KRYSTEXXA® (pegloticase)

November 1, 2023

Amgen to present data at ACR 2023 across expanded rheumatology pipeline and portfolio

October 31, 2023

Amgen reports third quarter financial results

October 30, 2023

Amgen announces webcast of 2023 third quarter financial results

October 24, 2023

Amgen announces 2023 fourth quarter dividend

October 23, 2023

Amgen presents new LUMAKRAS® (sotorasib) plus Vectibix® (panitumumab) data in patients with KRAS G12C-mutated metastatic colorectal cancer

October 21, 2023

Amgen presents new tarlatamab data in small cell lung cancer

October 19, 2023

Amgen to webcast investor call at esmo 2023

October 18, 2023

Amgen to present new research from oncology portfolio and pipeline at ESMO 2023

October 15, 2023

Amgen completes acquisition of Horizon Therapeutics plc

October 5, 2023

Amgen launches Partners of Choice network of eight leading oncology academic centers

September 19, 2023

Amgen presents new LUMAKRAS® (sotorasib) plus chemotherapy data in first-line KRAS G12C NSCLC at wclc

September 9, 2023

Amgen to present at the morgan stanley global healthcare conference

September 6, 2023

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

August 31, 2023

Amgen to present at the 2023 wells fargo healthcare conference and the citi global healthcare conference

August 30, 2023

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

August 25, 2023

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

August 20, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.